Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001178913-25-003403
Filing Date
2025-09-29
Accepted
2025-09-29 07:12:22
Documents
6
Period of Report
2025-09-29

Document Format Files

Seq Description Document Type Size
1 6-K zk2533810.htm 6-K 20283
2 ASSET TRANSFER AGREEMENT, DATED AS OF SEPTEMBER 29, 2025, BETWEEN HEMISPHERIAN A exhibit_10-1.htm EX-10.1 183450
3 COLLABORATION AND SHAREHOLDERS AGREEMENT, DATED AS OF SEPTEMBER 29, 2025, BETWEE exhibit_10-2.htm EX-10.2 136214
4 PRESS RELEASE exhibit_99-1.htm EX-99.1 22034
5 image00003.jpg GRAPHIC 13737
6 image00004.jpg GRAPHIC 2641
  Complete submission text file 0001178913-25-003403.txt   386050
Mailing Address 2 HAMAAYAN STREET MODI-IN TECHNOLOGY PARK MODI-IN Israel ISRAEL
Business Address 2 HAMAAYAN STREET MODI-IN TECHNOLOGY PARK MODI-IN Israel ISRAEL 972-8-642-9100
BioLineRx Ltd. (Filer) CIK: 0001498403 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-35223 | Film No.: 251352213
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)